EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Vamifeport: Monography of the First Oral Ferroportin Inhibitor

Federica Pilo, Emanuele Angelucci iD

Journal of Clinical Medicine · 18.09.2024 · 13 (18) · 5524

DOI: 10.3390/jcm13185524 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.09.2024. Verfasst von Federica Pilo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Transplant Center, Azienda Ospedaliera Brotzu, 09121 Cagliari, Italy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the last few years, several mechanisms that are involved in congenital diseases characterized by ineffective erythropoiesis have been described. Therefore, multiple new target drugs are being developed in preclinical models against the main regulators of normal erythropoiesis. Above all, the key mechanism that regulates systemic iron homeostasis, represented by the hepcidin–ferroportin axis, is considered to be the target for new therapies. The main hypothesis is that iron restriction, through blocking ferroportin (the unique iron transporter in mammals) in such diseases, ameliorates erythropoiesis. The action of vamifeport is different from the currently approved drugs in this setting since it acts straight on the ferroportin–hepcidin axis. The data presented in the sickle cell disease (SCD) Townes mouse model showed a preclinical proof-of-concept for the efficacy of oral ferroportin inhibitor. Vamifeport reduced hemoglobin concentration in red blood cells (RBCs) and diminished intravascular hemolysis and inflammation, improving hemodynamics and preventing vascular occlusive crises. On this basis, clinical trials were commenced in patients with SCD, non-transfusion-dependent (NTD) thalassemia and transfusion-dependent (TD) thalassemia. Preliminary data in NTD thalassemic patients also confirm the safety and efficacy in decreasing iron level. In conclusion, vamifeport represents a new option in the panorama of drugs targeting the hepcidin–ferroportin axis, but its efficacy is still under investigation as a single agent.

Schlagwörter

Stichwörter der Autor:innen

ferroportinhepcidinsickle cell diseasethalassemia

Autor:innen und Institutionen

  • Hematology and Transplant Center, Azienda Ospedaliera Brotzu, 09121 Cagliari, Italy.
  • Hematology and Cellular Therapy Center, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.

ORCID-Profile: Emanuele Angelucci

Zitieren

APA

Pilo, F., & Angelucci, E. (2024). Vamifeport: Monography of the First Oral Ferroportin Inhibitor. Journal of Clinical Medicine, 13(18), 5524. https://doi.org/10.3390/jcm13185524

Vancouver

Pilo F, Angelucci E. Vamifeport: Monography of the First Oral Ferroportin Inhibitor. Journal of Clinical Medicine. 2024;13(18):5524. doi:10.3390/jcm13185524

BibTeX
@article{Pilo2024,
  author = {Pilo, Federica and Angelucci, Emanuele},
  title = {Vamifeport: Monography of the First Oral Ferroportin Inhibitor},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {18},
  pages = {5524},
  doi = {10.3390/jcm13185524}
}
Kostenlos starten →